Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Accounts Payables (2016 - 2025)

Avanos Medical (AVNS) has disclosed Accounts Payables for 13 consecutive years, with $55.5 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 2.21% to $55.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.5 million through Dec 2025, up 2.21% year-over-year, with the annual reading at $55.5 million for FY2025, 2.21% up from the prior year.
  • Accounts Payables hit $55.5 million in Q4 2025 for Avanos Medical, up from $54.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $67.9 million in Q4 2022 to a low of $46.0 million in Q1 2025.
  • Historically, Accounts Payables has averaged $57.5 million across 5 years, with a median of $56.4 million in 2021.
  • Biggest five-year swings in Accounts Payables: fell 27.67% in 2021 and later rose 20.39% in 2022.
  • Year by year, Accounts Payables stood at $56.4 million in 2021, then grew by 20.39% to $67.9 million in 2022, then dropped by 17.08% to $56.3 million in 2023, then decreased by 3.55% to $54.3 million in 2024, then increased by 2.21% to $55.5 million in 2025.
  • Business Quant data shows Accounts Payables for AVNS at $55.5 million in Q4 2025, $54.2 million in Q3 2025, and $48.8 million in Q2 2025.